載入...
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comp...
Na minha lista:
| 發表在: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Taylor & Francis
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4801454/ https://ncbi.nlm.nih.gov/pubmed/27057436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1071007 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|